الفهرس 
Review of the literatureOnly 14 pages are availabe for public view
 |  | from | 321 |  |  |
| | | from | 321 | | |
Abstract
Cancer stem cells (CSCs) are the root of cancer disease, are responsible for tumor growth, development and metastasis. We showed a unique type of colorectal CSCs (CR4) which are established in CSCs lab, stony brook university, USA. Cells are totally different from commercial cell lines as both cell lines represent an ultra-low-passage of the patient-derived cancer cells. Cells were spontaneously immortalized, thereby representing more physiologically and clinically relevant cells, are enriched with CSCs and early progenitor cells, possess high tumorigenic, sphere-forming and clonogenic capacities and are extremely resistant to anti-cancer drugs. All the above makes these cell lines extremely valuable since they represent clinically and physiologically more relevant resource suitable for cancer research and anticancer drug development. New-generation taxoids was developed by Ojima’s lab at stony brook university; this drug can overcome drug resistance. SB-T-1214 exhibited high efficiency against colon cancer in vivo, inducing complete regression of drug-resistant colon tumor xenografts in all surviving mice with tumor growth delay up to 201 days. Such promising antitumor activity of SB-T-1214 specifically target tumor-specific CSCs by inhibiting some stemness-related signaling pathways and/or promoting their differentiation. Studied the SB-T-1214 cytotoxicity against colon cancer spheroids induced by CD133high/CD44high cells in 3D cultures. So, CR4 cell line is a good model for evaluation of CSC-targeted efficacy of anticancer drug candidates. NE-DHA-SB-T 1214 is highly effective for targeting CSC.